Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows

Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows
Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 trial shows. The combination also extended the time patients lived without signs of disease worsening compared with chemotherapy only, the company announced. The findings were recently presented by David Cibula, MD, PhD, the trial's lead researcher, in a presentation, "Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02)," at the Society of Gynecologic Oncologic 50thAnnual Meeting on Women’s Cancer, March 16–19, in Honolulu, Hawai. DCVAC/OvCa is an immunotherapy that activates dendritic cells — a kind of immune cells that play critical roles in T-cell activity. Specifically, dendritic cells “tell” T-cells what substances to recognize as harmful, such as cancer proteins. The treatment requires collecting dendritic cells from a patient and activating them in the lab by exposing them to dead cancer cells, before infusing them back into the patient’s body. Once inside the patient, these dendritic cells will expose T-cells to cancer-specific antigens, optimizing their punch against cancer cells. The SOV02 Phase 2 trial (
Subscribe or to access all post and page content.